At the San Antonio Breast Cancer Symposium (SABCS 2024), Dr. Maria Margarete Karsten and her team presented groundbreaking findings from the PRO B trial, a multicenter study evaluating the impact of alert-based patient-reported outcome (PRO) monitoring in metastatic breast cancer patients.
This innovative approach—leveraging digital symptom tracking via a mobile app—demonstrated significant clinical benefits:
- Clinically meaningful fatigue reduction across all patient subgroups
- 29% reduction in mortality in the intervention group compared to standard ca
- Improved symptom control and quality of life, particularly in late-stage disease
- Enhanced communication between patients and care teams, enabling early interventions and reducing unplanned hospitalizations
The PRO B trial highlights the transformative potential of digital health in oncology, showing that real-time patient feedback can drive better treatment adherence, proactive interventions, and improved survival outcomes.
With these findings, Dr. Maria Margarete Karsten and her colleagues are paving the way for a new era in metastatic breast cancer care, demonstrating how technology-driven patient monitoring can be successfully implemented in routine clinical practice.
